Longevity Health Holdings, Inc.

0.5510-0.05 (-8.17%)

Oct 29, 1:15:30 PM EDT · NasdaqCM · XAGE · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

981.74K

P/E (TTM)

Basic EPS (TTM)

-8.65

Dividend Yield

Recent Filings

8-K

Delisting shifts to OTC

9/12/25Sep 12, 2025

Longevity Health Holdings delisted from Nasdaq on September 12, 2025, after failing to meet minimum bid price rules, shifting its common stock and warrants to OTC markets. Operations remain unaffected, with continued SEC filings ensuring transparency. The company presses ahead with its merger plans for True Health Inc. Delisting stings, but liquidity holds.

10-Q

Q2 FY2025 results

8/14/25Aug 14, 2025

Longevity Health Holdings ramped up net sales to $503.6K in Q2 FY2025 ended June 30, 2025, a sharp 3,988% y/y jump from $12.3K, fueled by the Elevai Skincare acquisition that closed January 16, 2025 for $1.18M in stock and earnouts, including $660.8K in shares and $301.6K in contingent liabilities. Gross profit hit $302.7K with a 60.1% margin, yet operating expenses climbed 80% y/y to $2.16M, driving a $1.86M operating loss—wider q/q from Q1's $1.51M but 56% less severe y/y after stripping out prior forward purchase hits. Cash swelled to $1.55M on $3.15M in equity raises, offsetting $1.59M operating burn, while debt sits minimal at $16.7K under insurance financing; free cash flow not disclosed in the 10-Q. The Elevai bolt-on adds skincare muscle, but Nasdaq compliance hangs on the pending THPlasma merger. Litigation over old convertible notes drags on, with $1.18M accrued.

8-K

Longevity merges with plasma collector

7/14/25Jul 14, 2025

Longevity Health Holdings signed a merger agreement on July 14, 2025, to acquire True Health Inc., a plasma collection firm, in an all-stock deal valuing True Health at $59 million, or 19,666,667 shares of Longevity common stock at $3.00 per share, plus a $20 million earnout tied to performance milestones. The deal, which includes a separate $5 million cash purchase of FDA licenses contingent on Longevity securing $5 million in financing, aims to bolster plasma supply amid U.S. shortages, with True Health's centers expanding from two in FY24 to five in FY25 and projecting $10 million revenue in FY25. It terminated a prior merger with 20/20 Biolabs on July 8, 2025, without fees. Closing hinges on stockholder approvals and Nasdaq listing by November 30, 2025, yet integration risks loom large.

8-K

Merger extension announced

6/25/25Jun 25, 2025

Longevity Health Holdings extended its merger agreement with 20/20 Biolabs by pushing the due diligence deadline to July 8, 2025, from an earlier cutoff. This amendment, signed June 24, keeps the deal alive amid ongoing reviews. Yet the pact auto-terminates on that date without mutual consent. Risks loom if integration falters or approvals stall.

8-K

ATM sale extends cash runway

5/28/25May 28, 2025

Longevity Health Holdings sold 479,621 common shares at $4.08 average via its ATM facility on May 27, 2025, netting $1.96 million gross. This bolsters the balance sheet amid the pending 20/20 merger, extending cash runway to Q1 FY26 without merger growth. Funds support merger costs and longevity product delivery. Merger risks loom large.

About

Longevity Health Holdings, Inc., a bio-aesthetics company, focuses on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company utilizes Carmell Secretome and Elevai Exosomes to support skin and hair health. Its Carmell Secretome consists of growth factors, proteins, and peptides extracted from allogeneic human platelets; and Elevai Exosomes constains growth factors, cytokines, peptides, and other small molecules involved in the body's natural healing process. The company also develops a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Corporation and changed its name to Longevity Health Holdings, Inc. in March 2025. Longevity Health Holdings, Inc. was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

CEO

Mr. Rajiv Sarman Shukla

IPO

9/23/2021

Website

https://www.carmellcosmetics.com

Employees

Sector

Consumer Defensive

Industry

Household & Personal Products